Baldwin Brothers LLC Cara Therapeutics, Inc. Transaction History

Baldwin Brothers LLC

$1.43 Billion
Q3 2024

A detailed history of Baldwin Brothers LLC transactions in Cara Therapeutics, Inc. stock. As of the latest transaction made, Baldwin Brothers LLC holds 500 shares of CARA stock, worth $2,680. This represents 0.0% of its overall portfolio holdings.

Number of Shares

500

Previous 3,500 85.71%

Holding current value

$2,680

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 15, 2024	SELL	$0.26 - $0.38 $780 - $1,140	-3,000 Reduced 85.71%	500 $0
Q4 2023 Jan 08, 2024	SELL	$0.6 - $1.65 $7,510 - $20,653	-12,517 Reduced 78.15%	3,500 $2,000
Q1 2023 Apr 21, 2023	SELL	$4.89 - $12.27 $7,334 - $18,405	-1,500 Reduced 8.56%	16,017 $78,000
Q4 2022 Jan 27, 2023	SELL	$8.88 - $12.77 $7,192 - $10,343	-810 Reduced 4.42%	17,517 $0
Q1 2022 Apr 13, 2022	BUY	$9.94 - $12.65 $52,950 - $67,386	5,327 Added 40.98%	18,327 $223,000
Q4 2021 Jan 14, 2022	SELL	$11.99 - $18.14 $35,970 - $54,420	-3,000 Reduced 18.75%	13,000 $158,000
Q2 2021 Jul 30, 2021	BUY	$12.38 - $29.19 $8,331 - $19,644	673 Added 4.39%	16,000 $228,000
Q1 2021 Apr 08, 2021	SELL	$15.07 - $21.71 $15,070 - $21,710	-1,000 Reduced 6.12%	15,327 $333,000
Q4 2020 Jan 12, 2021	SELL	$12.72 - $16.16 $8,904 - $11,312	-700 Reduced 4.11%	16,327 $247,000
Q1 2020 Apr 15, 2020	SELL	$9.12 - $17.78 $48,582 - $94,714	-5,327 Reduced 23.83%	17,027 $225,000
Q3 2018 Oct 26, 2018	SELL	$17.57 - $23.95 $17,570 - $23,950	-1,000 Reduced 4.28%	22,354 $535,000
Q3 2017 Oct 26, 2017	BUY	$12.6 - $16.34 $294,260 - $381,604	23,354	23,354 $320,000

Others Institutions Holding CARA

# of Institutions

Shares Held

12.8M

Call Options Held

Put Options Held

View Full List

About Cara Therapeutics, Inc.

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $288M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

More about CARA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baldwin Brothers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Baldwin Brothers LLC with notifications on news.

Account

Baldwin Brothers LLC Cara Therapeutics, Inc. Transaction History